ArticleFrontiers in chemistry2020
Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells.
Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Recent Advances in Integrating Graphene into Polymeric Nanocomposite Hydrogels for Biomedical Applications.Macromolecular bioscience · 2026Review
- Exploring the Impact of Nanotherapeutics on Histone H3 and H4 Acetylation Enrichment in Cancer Epigenome: A Systematic Scoping Synthesis.Epigenomes · 2025Review
- Recent progress in topical and transdermal approaches for melanoma treatment.Drug delivery and translational research · 2025Review
- Novel ultrathin ferrous sulfide nanosheets: Towards replacing black phosphorus in anticancer nanotheranostics.Bioactive materials · 2025Article
- Nanostructured Coatings Based on Graphene Oxide for the Management of Periprosthetic Infections.International journal of molecular sciences · 2024Article
- Interaction of Graphene Oxide Particles and Dendrimers with Human Breast Cancer Cells by Real-Time Microscopy.Pharmaceutics · 2023Article
- Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems.Pharmaceutics · 2023Review
- Graphene-based nanomaterials for stimuli-sensitive controlled delivery of therapeutic molecules.Frontiers in bioengineering and biotechnology · 2023Review
- Recent biomedical advancements in graphene oxide- and reduced graphene oxide-based nanocomposite nanocarriers.Biomaterials research · 2022Review
- Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments.Neoplasia (New York, N.Y.) · 2022Review
- Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy.Nanomaterials (Basel, Switzerland) · 2022Article
- Gold Nanoparticles and Graphene Oxide Flakes Synergistic Partaking in Cytosolic Bactericidal Augmentation: Role of ROS and NOX2 Activity.Microorganisms · 2021Article
- Histone Deacetylase Inhibitor Trichostatin A Reduces Endothelial Cell Proliferation by Suppressing STAT5A-Related Gene Transcription.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since Graphene discovery, their associated derivate nanomaterials, Graphene Oxide (GO) and reduced-GO were in the forefront of continuous developments in bio-nano-technology due to unique physical-chemical properties. Although GO nano-colloids (GON) were proposed as drug release matrix for targeting cancer cells, there is still a concern regarding its cytotoxicity issues. In this study, we report on the fabrication of functional GON bio-coatings by Matrix-Assisted Pulsed Laser Evaporation (MAPLE) to be used as drug carriers for targeting melanoma cells. We first performed a thorough
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.